Covid-19 Information: Reside Updates – The New York Instances
Here’s what you need to know:
Credit…Dico Soliz/Associated Press
In Bolivia, bodies are piling up at homes and on the streets again, echoing the horrific images of last summer, when a deadly surge in coronavirus infections overwhelmed the country’s fragile medical system. The Bolivian police say that in January they recovered 170 bodies of people thought to have died from Covid-19, and health officials say intensive-care units are full.
“When 10 or 20 patients die, their beds are full again in a few hours,” said Carlos Hurtado, a public health epidemiologist in Santa Cruz, Bolivia’s largest city.
The resurgence of the virus in Bolivia is part of a larger second wave throughout Latin America, where some of the world’s strictest quarantine measures are giving way to pandemic fatigue and concerns about the economy.
The International Monetary Fund said on Monday that it was revising its 2021 growth forecast for Latin America and the Caribbean to 4.1 percent from 3.6 percent. Warning that the surge in cases could threaten an economic recovery that is already expected to take longer than in other parts of the world, the fund predicted that regional output will not return to pre-pandemic levels until 2023.
While the number of new cases is falling, deaths remain at near-record highs in many parts of the region, just as some governments begin vaccination efforts.
Brazil and Mexico have each been averaging over 1,000 daily Covid-19 deaths for weeks; their total pandemic death toll is now surpassed only by that of the United States. Deaths in Brazil have matched their summer peak, while in Mexico they are far higher than any earlier peak, though they have begun falling in recent days.
In Bolivia last summer, mortality figures reviewed by The New York Times suggested that the country’s real death toll was nearly five times the official tally, indicating that Bolivia had suffered one of the world’s worst epidemics. About 20,000 more people died from June through August than in past years, according to a Times analysis — a vast number in a country of about 11 million people.
Bolivia is now reporting an average of 60 coronavirus deaths per day, approaching the numbers from last summer.Experts believe the higher mortality rate is caused by the more contagious virus variants originating in neighboring Brazil and elsewhere, but they lack the instruments to analyze the virus’s genetic code.
Despite the rising death rate, the Bolivian authorities have not implemented the quarantine measures used to help curb the virus’s first wave a year ago. Officials in Bolivia and other Latin American nations are touting their nascent vaccination programs as a reason to avoid lockdowns, even though few countries in the region beyond Brazil have procured a meaningful number of doses.
Only 20,000 vaccine doses have arrived in Bolivia, although the government says it plans to vaccinate eight million people by September.
Anatoly Kurmanaev and
|United States ›||United StatesOn Feb. 8||14-day change|
|World ›||WorldOn Feb. 8||14-day change|
U.S. vaccinations ›
Credit…Ina Fassbender/Agence France-Presse — Getty Images
As the European Union began its campaign to line up vaccines, it was slower off the mark, focused on prices while the United States and Britain made money no object, and succumbed to an abundance of regulatory caution. All of those things have left the bloc flat-footed as drugmakers fall behind on their promised orders.
But the 27 countries of the European Union are also attempting something they have never tried before and have broken yet another barrier in their deeper integration — albeit shakily — by casting their lot together in the vaccine hunt.
In doing so, they have inverted the bloc’s usual power equation. Bigger, richer countries like Germany and France — which could have afforded to sign contracts directly with drugmakers, as the United States and Britain did — saw their vaccine campaigns delayed by the more cumbersome joint effort, while smaller countries wound up with better supply terms than they were likely to have negotiated on their own.
For the bulk of E.U. nations, that experiment has been beneficial. But it has not necessarily been greeted happily in the wealthiest countries, and it has left leaders like Chancellor Angela Merkel of Germany and President Emmanuel Macron of France open to criticism at home.
They and E.U. leaders have nonetheless stood by their decision and the impulse for solidarity, even as the finger-pointing has begun.
“What would people have said if Germany and France had been in competition with one another for the purchase or production of vaccines? That would have been chaos,” Mr. Macron said at a news conference on Friday after a virtual meeting with Ms. Merkel. “That would have been counterproductive, economically and from a public health perspective, because we will only come out of this pandemic when we have vaccinated enough people in Europe.”
But even as the leaders of Europe’s traditional power duo talked up the 2.3 billion doses ordered as an indication of the wisdom of a joint approach, they conceded that a full campaign could not be expected before March.
Just over 3 percent of E.U. nationals had received at least one vaccine dose by the end of last week, compared with 17 percent in Britain and 9 percent in the United States.
Credit…Elmond Jiyane for Gcis, via Reuters
A million doses of the AstraZeneca-Oxford vaccine had been shipped recently to South Africa from India. The first injections were set for Wednesday. After weeks of rich countries vaccinating doctors and nurses against the coronavirus, a respite from the anxiety and the trauma seemed to be nearing in South Africa, too.
Then, all of a sudden, the plans were shelved. The country’s leaders on Sunday ordered the rollout of the vaccine halted after a clinical trial failed to show that it could prevent people from getting mild or moderate cases of Covid-19 caused by the coronavirus variant that has overrun the country.
The new findings from South Africa were far from conclusive: They came from a small clinical trial that enrolled fewer than 2,000 people. And they did not preclude what some scientists say is the likelihood that the vaccine protects against severe disease from the variant — a key indicator of whether the virus will overwhelm hospitals and kill people.
But even if the vaccine is shown to prevent severe disease, scientists say, what happened in South Africa is a warning to the world. As quickly as scientists developed vaccines, the virus has seemed to evolve even more quickly. Instead of eradicating the virus, scientists now foresee months, if not years, of vaccine makers continually having to update their booster shots to protect against new variants.
And if the variant first seen in South Africa, now present in 32 countries, becomes the dominant form of the virus elsewhere, those countries could face a far slower crawl out of the pandemic.
The news was not all bad. Other vaccines offer some protection against the variant from South Africa, though less than against earlier versions of the virus. Among them is Johnson & Johnson’s vaccine, which prevented hospitalizations and deaths in clinical trials in the country. Despite not yet being authorized there, it could be rolled out to some health workers by mid-February as part of what officials vaguely described as “a research project.”
AstraZeneca is working to produce a version of its vaccine that can protect against the variant from South Africa by the fall.
Still, the findings rattled scientists, undercutting the notion that vaccines alone will stop the spread of the virus anytime soon. And they led to new, and more urgent, demands that richer countries donate doses to poorer countries that could become breeding grounds for mutations if the virus spreads unchecked.
A number of coronavirus variants are raising worries that they may draw out the pandemic or make vaccines less effective. Here are four that have been in the news lately and what we know about them:
B.1.1.7. This variant, which first emerged in Britain, is thought to be about 50 percent more infectious than other versions of the coronavirus, and preliminary evidence suggests that it is about 35 percent more deadly. Yet vaccines appear to work well against it. It has been detected in more than 70 countries, including the United States, where it is doubling roughly every 10 days. Experts predict that it could be the country’s dominant source of infection by March, potentially bringing a surge of new cases and increased risk of death. Learn more about B.1.1.7 >>
B.1.351. Scientists are concerned about this variant, which was first identified in South Africa, because vaccines may be less effective against it. South Africa halted use of the AstraZeneca-Oxford vaccine on Sunday after evidence emerged that the drug did not protect against mild or moderate illness caused by B.1.351. The variant has spread to at least 24 countries, including the United States, where it has been detected in Maryland, South Carolina and Virginia. The Food and Drug Administration is preparing a plan for updating vaccines if the variant surges in the United States.
P.1. This variant, which emerged in Brazil, is a close relative of B.1.351 and may be able to overcome the immunity developed after infection by other variants. It has spread to several countries, including the United States, where it has been detected in Minnesota and Oklahoma.
CAL.20C. This variant, which was discovered in California, was found in more than half of samples tested in Los Angeles. It is not yet clear whether it is more infectious.
For more information and the latest news on these variants, check out our tracker.
Credit…Anna Moneymaker for The New York Times
House Democrats on Monday rolled out a main plank of President Biden’s stimulus plan, proposing legislation to send direct payments of $1,400 to Americans earning up to $75,000 and households with incomes up to $150,000.
The plan, drafted the day before key committees are scheduled to being meeting to consider it, is at odds with proposals from some Republicans and moderate Democrats who want to curtail eligibility for direct payments, targeting it to lower-income people. Mr. Biden has said he is open to such modifications.
For now, the measure would allow individuals paid up to $100,000 and households up to $200,000 to be eligible for some payment, though the size of the checks would phase out gradually for those with incomes above $75,000, or $150,000 for a family.
The bill, unveiled by Representative Richard E. Neal, Democrat of Massachusetts and the chairman of the Ways and Means Committee, was one of a series that Democrats presented on Monday ahead of a week of legislative work to solidify the details of Mr. Biden’s stimulus proposal.
The decision to keep the income cap at the same level as the last round of stimulus payments comes after days of debate among the House Democratic caucus over the size of the checks. Some moderates pushed to restrict the full amount to those who make $50,000 or less and households making up to $100,000.
The legislation also includes significant changes to the tax code and an increase in an extension of weekly federal unemployment benefits. It would raise the $300-a-week payment to $400 a week and continue the program — currently slated to begin lapsing in March — through the end of August.
The $1.9 trillion plan would also provide for billions of dollars for schools, colleges, small businesses, and a provision that would increase the federal minimum wage to $15 by 2025, a progressive priority.
Credit…Max Whittaker for The New York Times
With nearly a year of coronavirus experience behind them, leaders at many universities in the United States ushered in the new term pledging not to repeat the errors of last year, when infection rates soared on campuses and in the surrounding communities.
But although most schools have pledged to increase testing, it is an expensive proposition at a time when many are struggling financially, and not all are testing students as often as recommended by public health experts.
The plans to keep the virus under control, for example, at the University of Michigan — which had more than 2,500 confirmed cases by the end of the fall semester — included increasing testing, offering more courses online, limiting dorm rooms to one occupant and offering no tolerance for rules violations. Yet already more than 1,000 new virus cases have been announced by the school since Jan. 1.
Other universities across the country have also encountered obstacles to a smooth spring, including the unexpected challenge of emerging variants — detected in recent days at the University of Texas at Austin, the University of Miami, Tulane University in New Orleans and the University of California, Berkeley — and the more common problem of recalcitrant students.
At Vanderbilt University in Nashville, students returning after winter break were required to be tested upon arrival and were then asked to avoid social interactions while awaiting results. But some had other ideas.
“We identified a cluster of positive Covid-19 cases linked to students who did not follow the arrival shelter-in-place rules,” a campuswide email reported on Jan. 23, blaming two student organizations for violating protocols. “More than 100 students are now in quarantine.”
The foundation of most university plans for the spring semester centers on increased testing to identify infected students before they display symptoms, and then placing them in isolation. The testing push has grown since July, when a study recommended that students be tested twice a week to better detect asymptomatic infections.
The American College Health Association later embraced the idea, issuing guidelines in December. “For the spring, we specifically recommend that all students are tested on arrival and twice a week thereafter if possible,” said Gerri Taylor, a co-chair of the organization’s Covid-19 task force.
Ms. Taylor said her organization did not know what percentage of schools had adopted the recommendations, and a survey of colleges across the country revealed a variety of requirements, ranging from voluntary testing to mandatory testing twice a week.
Credit…Jake Crandall/The Montgomery Advertiser, via Associated Press
An expansion of Alabama’s lagging Covid-19 vaccination program drew large crowds of people on Monday as the state opened the last of eight new sites for inoculations.
The centers are a huge expansion of a vaccination program that has struggled to gain traction. Only 7.7 percent of eligible Alabamians have gotten at least one vaccine dose, according to a New York Times database, placing the state last among the 50 states and the District of Columbia.
Long lines of cars formed outside a downtown stadium in Selma, a hospital parking deck in Dothan and the site of a former shopping mall in Montgomery, where teams of workers delivered vaccinations through car windows. Shots were available to anyone over 65 and to select groups that included educators, farm workers, grocery employees and state legislators.
Before the centers opened, only about 700,000 medical workers, emergency medical workers, nursing home residents and people 75 and over were eligible to be vaccinated. The opening of the eight centers coincided with an expansion of eligibility for vaccination that raised that total to about 1.5 million.
Each of the eight centers is equipped to give 5,000 vaccinations by week’s end. By comparison, workers at Southeast Health medical center in Dothan had vaccinated fewer than 4,700 people since vaccines first became available in late December, the hospital spokesman, Mark Stewart, said in an interview.
Mr. Stewart said thousands of applicants had already sought appointments in the Dothan area. About 900 vaccinations were to be given out by day’s end, he said.
“It’s so good to see people.”
That was Naomi Osaka, the three-time Grand Slam champion, moments after her first-round win on Monday afternoon at the Australian Open. She stood at a microphone on the court at Rod Laver Arena and peered up at a crowd that seemed, if not normal, then something like it.
That was how it was on Monday across the grounds of Melbourne Park, where international sports returned, however temporarily, to something like it was before the pandemic.
Spectators lined up for tickets. They waited in security lines, pondered whether to order burgers or fish and chips, and decided how many $13 beers they could stomach.
The tournament could safely occur now only because the Grand Slam tennis season happens to start in a country that has arguably controlled Covid-19 better than anywhere else, thanks to months of enforced lockdowns, closed borders, and thorough testing and contact tracing. Just 909 people in Australia, which has a population of more than 25 million, have died of Covid-19. The country has averaged a half-dozen cases a day during the past two weeks, nearly all of them international arrivals.
Compromises have been made at this year’s event: Spectators are capped at 30,000 per day, about half the number that would usually attend. But their roars were appreciated more than ever.
“That’s one of the biggest motivations that we have, the source where we draw our energy and strength and motivation,” said Novak Djokovic, the world No. 1. “Especially at my age and stage of my career, I’m looking to feed off that energy from the crowd.”